INmune Bio Inc. has announced new neuroimaging data from its Phase 2 MINDFuL trial evaluating XPro1595 in patients with early Alzheimer's disease and elevated neuroinflammation. The results, which will be presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference held December 1-4, 2025, indicate that XPro1595 may slow disease progression, as evidenced by a trend toward reduced cortical disarray in dose-compliant participants. Additional MRI analyses from the trial are ongoing, with further data expected to be reported in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-118699), on December 05, 2025, and is solely responsible for the information contained therein.